Paul S Mueller

US Patent:

7550469, Jun 23, 2009

Filed:

Dec 21, 2006

Appl. No.:

11/643594

Inventors:

James A Hendrix - Hillsborough NJ, US
Joseph T Strupczewski - Flemington NJ, US
Kenneth Bordeau - Kintnersville PA, US
Matthias Urmann - Eschborn, DE
Gregory Shutske - Pittstown NJ, US
Horst Hemmerle - Indianapolis IN, US
John G Jurcak - Bethlehem PA, US
Harpal Gill - West Chester OH, US
Franz J Weiberth - Ringoes NJ, US
Thaddeus Nieduzak - Bridgewater NJ, US
Sharon Anne Jackson - Whitehouse Station NJ, US
Paul Justin Mueller - Hoboken NJ, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 31/496
C07D 495/04
C07D 498/04
A61K 31/4525
A61K 31/4535
A61K 31/551
C07D 333/66
C07D 409/12
C07D 409/14
C07D 413/041

US Classification:

51425404, 51425406, 540575, 544355, 544357, 544362, 544363, 544364, 544370, 544373, 544376, 546126, 546198, 546199, 546202

Abstract:

The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e. g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

US Patent:

7777042, Aug 17, 2010

Filed:

Dec 6, 2006

Appl. No.:

11/567421

Inventors:

Bruce Baron - Westfield NJ, US
Patrick Jimonet - Villepreux, FR
John G. Jurcak - Bethlehem PA, US
Stephen J. Shimshock - Hillsborough NJ, US
Rosy Sher - Bridgewater NJ, US
Paul J. Mueller - Hoboken NJ, US
Jennifer Beall - Geneva IL, US
Matthieu Barrague - Union City NJ, US
Joseph W. Guiles - Lafayette CO, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 31/535
C07D 211/30

US Classification:

546225, 5142355

Abstract:

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I,.

US Patent:

20030229066, Dec 11, 2003

Filed:

Feb 19, 2002

Appl. No.:

10/078215

Inventors:

James Hendrix - Hillsborough NJ, US
Joseph Strupczewski - Flemington NJ, US
Kenneth Bordeau - Kintnersville PA, US
Sarah Brooks - Belmont CA, US
Horst Hemmerle - Indianapolis IN, US
Matthias Urmann - Eschborn, DE
Paul Mueller - Hoboken NJ, US

International Classification:

C07D471/02
C07D491/02
A61K031/4745
A61K031/407
A61K031/46
A61K031/337

US Classification:

514/210160, 514/300000, 514/304000, 514/412000, 546/124000, 546/113000, 548/950000, 548/453000

Abstract:

The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

US Patent:

20040030137, Feb 12, 2004

Filed:

Feb 19, 2002

Appl. No.:

10/078206

Inventors:

James Hendrix - Hillsborough NJ, US
Joseph Strupczewski - Flemington NJ, US
Kenneth Bordeau - Kintnersville PA, US
Matthias Urmann - Eschborn, DE
Gregory Shutske - Pittstown NJ, US
Horst Hemmerle - Indianapolis IN, US
John Jurcak - Bethlehem PA, US
Harpal Gill - West Chester OH, US
Franz Weiberth - Ringoes NJ, US
Thaddeus Nieduzak - Bridgewater NJ, US
Sharon Jackson - Whitehouse Station NJ, US
Paul Mueller - Hoboken NJ, US

International Classification:

C07F005/02

US Classification:

546/013000

Abstract:

The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

US Patent:

20050107389, May 19, 2005

Filed:

Oct 7, 2004

Appl. No.:

10/960399

Inventors:

James Hendrix - Hillsborough NJ, US
Kenneth Bordeau - Kintnersville PA, US
Matthias Urmann - Eschborn, DE
Gregory Shutske - Pittstown NJ, US
Horst Hemmerle - Noblesville IN, US
John Jurcak - Bethlehem PA, US
Harpal Gill - West Chester OH, US
Franz Weiberth - Ringoes NJ, US
Thaddeus Nieduzak - Bridgewater NJ, US
Sharon Jackson - Whitehouse NJ, US
Paul Mueller - Hoboken NJ, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C07D471/02
C07D487/04
A61K031/503
A61K031/4745

US Classification:

514248000, 514300000, 544236000, 546117000

Abstract:

The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.